title: Altered activation of peripheral CD8+ T cells in pediatric Crohn's disease.
abstract: Although Crohn's disease (CD) is an extensively investigated autoimmune condition, knowledge on early phase activation of lymphocytes, especially CD8+ Tc cells is scarce. Our aim was to investigate the calcium influx characteristics of CD8+ cells upon activation as well as the expression and function of Kv1.3 and IKCa1 lymphocyte potassium channels.
  
  
  
  We took peripheral blood from 12 healthy controls, 23 CD children on conventional therapy and 6 severe CD children before and after infliximab therapy. Intracellular calcium levels were monitored in CD8+ lymphocytes using flow cytometry.
  
  
  
  In CD treated with standard therapy calcium response during activation was elevated. This was not affected by the inhibition of Kv1.3 or IKCa1 potassium channels. After the switch to infliximab potassium channel function and expression of CD8+ lymphocytes were comparable to healthy controls in severe CD.
  
  
  
  Calcium handling of CD8+ lymphocytes is altered in pediatric CD, which is normalized by infliximab therapy.
authors.affiliation: First Department of Pediatrics, Semmelweis University, Bókay u. 53, H-1083 Budapest, Hungary; Department of Dietetics and Nutrition Sciences, Faculty of Health Sciences, Semmelweis University, Vas u. 17, H-1088 Budapest, Hungary. Electronic address: orbancsaba1988@gmail.com.
authors.forename: Csaba
authors.initials: C
authors.lastname: Orbán
authors.affiliation: First Department of Pediatrics, Semmelweis University, Bókay u. 53, H-1083 Budapest, Hungary.
authors.forename: Dolóresz
authors.initials: D
authors.lastname: Szabó
authors.affiliation: First Department of Pediatrics, Semmelweis University, Bókay u. 53, H-1083 Budapest, Hungary.
authors.forename: Anna
authors.initials: A
authors.lastname: Bajnok
authors.affiliation: Department of Laboratory Medicine, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary; Bionics Innovation Centre, 1089 Szentkirályi u 8, H-1085 Budapest, Hungary.
authors.forename: Barna
authors.initials: B
authors.lastname: Vásárhelyi
authors.affiliation: First Department of Pediatrics, Semmelweis University, Bókay u. 53, H-1083 Budapest, Hungary; MTA-SE, Pediatrics and Nephrology Research Group, Bókay u. 53, H-1083 Budapest, Hungary.
authors.forename: Tivadar
authors.initials: T
authors.lastname: Tulassay
authors.affiliation: First Department of Pediatrics, Semmelweis University, Bókay u. 53, H-1083 Budapest, Hungary; MTA-SE, Pediatrics and Nephrology Research Group, Bókay u. 53, H-1083 Budapest, Hungary.
authors.forename: András
authors.initials: A
authors.lastname: Arató
authors.affiliation: First Department of Pediatrics, Semmelweis University, Bókay u. 53, H-1083 Budapest, Hungary; MTA-SE, Pediatrics and Nephrology Research Group, Bókay u. 53, H-1083 Budapest, Hungary.
authors.forename: Gábor
authors.initials: G
authors.lastname: Veres
authors.affiliation: First Department of Pediatrics, Semmelweis University, Bókay u. 53, H-1083 Budapest, Hungary; MTA-SE, Pediatrics and Nephrology Research Group, Bókay u. 53, H-1083 Budapest, Hungary.
authors.forename: Gergely
authors.initials: G
authors.lastname: Toldi
mesh_terms: D000293:Adolescent; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001775:Blood Circulation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D020013:Calcium Signaling; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels / Q000378:metabolism*; D051664:Kv1.3 Potassium Channel / Q000378:metabolism*; D008213:Lymphocyte Activation; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D018501:Antirheumatic Agents; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; C496923:KCNN4 protein, human; D051664:Kv1.3 Potassium Channel; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: CD8; Calcium influx; Crohn’s disease; Infliximab; T cell